Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

Labcorp (LH) reported robust second-quarter 2025 results, with adjusted EPS of $4.35, up 10.4% year-over-year and exceeding consensus by 5.1%, alongside revenues of $3.53 billion, a 9.5% increase year-over-year and 1.14% above estimates. This strong performance, driven by organic growth, acquisitions, and favorable currency impacts, also saw significant margin expansion. Consequently, Labcorp raised its full-year 2025 guidance for revenues, adjusted EPS, and free cash flow, signaling confidence in its business strength and leading to a 1.8% rise in its shares during pre-market trading.

Analysis

Labcorp Holdings (LH) delivered a robust second-quarter 2025 performance, exceeding consensus estimates on both top and bottom lines. Adjusted EPS of $4.35 represented a 10.4% year-over-year increase and a 5.1% beat, while revenues grew 9.5% to $3.53 billion, surpassing forecasts by 1.1%. This growth was well-diversified, stemming from 5.4% organic growth, 3.5% from acquisitions, and a 0.6% tailwind from foreign currency. Both core segments demonstrated strength, with Diagnostics Laboratories revenues rising 8.9% and the Biopharma Laboratory Services segment growing 11%. Critically, the company exhibited significant operational leverage, expanding its adjusted operating margin by 179 basis points to 13.2% despite higher costs. This robust operational performance and improved outlook prompted management to raise its full-year 2025 guidance for revenue, adjusted EPS, and free cash flow, signaling strong confidence in underlying business momentum and strategic initiatives such as new oncology test launches.

Key Decisions for Investors

• The comprehensive beat-and-raise quarter, characterized by significant margin expansion and improved free cash flow guidance, provides a strong basis for investors to affirm or initiate a bullish position on Labcorp.
• Investors should monitor the company's ability to execute against its newly raised 2025 guidance, particularly the forecasted revenue growth of 7.5%-8.6% and adjusted EPS of $16.05-$16.50, as meeting these targets is now priced into expectations.
• Pay close attention to future margin trends, as the 179 bps expansion in adjusted operating margin demonstrates significant operational leverage that could drive further earnings outperformance if sustained.
• While the results are strong, it may be prudent to assess Labcorp's valuation and growth trajectory relative to the higher-ranked peers mentioned in the broader medical space to ensure optimal capital allocation.